J. Goldman & Co’s 4D Molecular Therapeutics FDMT Stock Holding History

J. Goldman & Co’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-48,287	Closed	-$2M	–	464
2020 Q4	$2M	Buy	+48,287	New	+$1.99M	0.1%	193

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

J. Goldman & Co's FDMT Position: Q1 2021 in Review

J. Goldman & Co sold out of 4D Molecular Therapeutics (FDMT) in Q1 2021, closing a stake of 48,287 shares — an estimated $2M sold.

J. Goldman & Co first reported a position in FDMT in Q4 2020 and held it in 1 quarter. The position peaked at $2M in Q4 2020. 64 funds tracked by Wall St. Rank hold FDMT as of Q1 2021.

J. Goldman & Co reported no remaining 4D Molecular Therapeutics position as of Q1 2021 after selling out during the quarter.
J. Goldman & Co sold 48,287 4D Molecular Therapeutics shares in Q1 2021, an estimated $2M.
J. Goldman & Co first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 1 quarter.
J. Goldman & Co's 4D Molecular Therapeutics position peaked at $2M in Q4 2020.
64 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.